Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab added to carboplatin and etoposide for first-line extensive-stage small cell lung cancer
ISRCTN14095893Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Jun 2011; status: completed.
02
Drugs
ipilimumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ISRCTN14095893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14095893.